However, a post-hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) and Irbesartan Diabetic Nephropathy Trial (IDNT) trials demonstrated that the UACR- and BP- lowering effects of ARB therapy are attenuated in patients with diabetic nephropathy and high sodium intake15. Here, AGT is linked to diabetic kidney disease.